Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)

NCT06917690 is registered in ClinicalTrials.gov with Chiesi Farmaceutici S.p.A. as lead sponsor.

NCT NCT06917690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06917690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)
Lead sponsor
Chiesi Farmaceutici S.p.A.
Phase
Phase 3
Overall status
Recruiting
Start date
April 18, 2025
Completion date
September 30, 2029
Enrollment
6 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

collagen diseases, congenital abnormalities, connective tissue disease, epidermolysis bullosa, epidermolysis bullosa, dystrophic, epidermolysis bullosa, junctional, genetic diseases, inborn, junctional epidermolysis bullosa, skin abnormalities, skin diseases